α-Synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma

FASEB Journal

Volumn 17, Issue 13, 2003, Pages

  El Agnaf, Omar M A ^a   Salem, Sultan A ^a   Paleologou, Katerina E ^a   Cooper, Leanne J ^a   Fullwood, Nigel J ^a   Gibson, Mark J ^b   Curran, Martin D ^b   Court, Jennifer A ^c   Mann, David M A ^d   Ikeda, Shu Ichi ^e   Cookson, Mark R ^f   Hardy, John ^f   Allsop, David ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d HOPE HOSPITAL   (United Kingdom)

^e SHINSHU UNIVERSITY   (Japan)

^f NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Amyloid; Dementia with Lewy bodies; Neurodegeneration

Indexed keywords

EID: 85109083933     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.03-0098fje     Document Type: Article

References (44)

1. Jakes, R., Spillantini, M. G., and Goedert, M. (1994) Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27–32
2. Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y., and Saitoh, T. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 11282–11286
3. 53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson’s disease. FEBS Lett. 440, 67–70
4. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T., Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97, 571–576
5. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science 276, 2045–2047
6. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson’s disease. Nat. Gen. 18, 106–108
7. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839–840
8. Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M., Trojanowski, J. Q., and Iwatsubo, T. (1998) Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879–884
9. Spillantini, M. G., Crowther, R. A., Jakes, R., Cairns, N. J., Lantos, P. L., and Goedert, M. (1998) Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205–208
10. Gai, W. P., Power, J. H., Blumbergs, P. C., and Blessing, W. W. (1998) Multiple-system atrophy: a new α-synuclein disease? Lancet 352, 547–548
11. El-Agnaf, O. M. A., and Irvine, G. B. (2000) Formation and properties of amyloid-like fibrils derived from α-synuclein and related proteins. J. Struct. Biol. 130, 300–309
12. George, J. M., Jin, H., Woods, W. S., and Clayton, D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 2, 361–372
13. Kholodilov, N. G., Neystat, M., Oo, T. F., Lo, S. E., Larsen, K. E., Sulzer, D., and Burke, R. E. (1999) Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J. Neurochem. 73, 2586–2599
14. Stefanis, L., Kholodilov, N., Rideout, H. J., Burke, R. E., and Greene, L. A. (2001) Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells. J. Neurochem. 76, 1165–1176
15. van der Putten, H., Wiederhold, K. H., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W. P., Ruegg, M. A., et al. (2000) Neuropathology in mice expressing human α-synuclein. J. Neurosci. 20, 6021–6029
16. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo, P. E., Shinsky, N., Verdugo, J. M., Armanini, M., Ryan, A., et al. (2000) Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 1, 239–252
17. Souza, J. M., Giasson, B. I., Lee, V. M., and Ischiropoulos, H. (2000) Chaperone-like activity of synucleins. FEBS Lett. 474, 116–119
18. Sharon, R., Goldberg, M. S., Bar-Josef, I., Betensky, R. A., Shen, J., and Selkoe, D. J. (2001) α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl. Acad. Sci. USA 98, 9110–9115
19. Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A., and Selkoe, D. J. (2003) The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583–595
20. Hashimoto, M., Hsu, L. J., Rockenstein, E., Takenouchi, T., Mallory, M., and Masliah, E. (2002) α-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J. Biol. Chem. 277, 11465–11472
21. Seo, J. H., Rah, J. C., Choi, S. H., Shin, J. K., Min, K., Kim, H. S., Park, C. H., Kim, S., Kim, E. M., Lee, S. H., et al. (2002) α-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 13, 1826–1828
22. El-Agnaf, O. M., Jakes, R., Curran, M. D., Middleton, D., Ingenito, R., Bianchi, E., Pessi, A., Neill, D., and Wallace, A. (1998) Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like filaments. FEBS Lett. 440, 71–75
23. Turnbull, S., Tabner, B. J., El-Agnaf, O. M. A., Moore, S., Davies, Y., and Allsop, D. (2001) α-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic. Biol. Med. 30, 1163–1170
24. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H. A., Kittel, A., and Saitoh, T. (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 2, 467–475
25. Jakowec, M. W., Petzinger, G. M., Sastry, S., Donaldson, D. M., McCormack, A., and Langston, J. W. (1998) The native form of α-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls. Neurosci. Lett. 253, 13–16
26. Borghi, R., Marchese, R., Negro, A., Marinelli, L., Forloni, G., Zaccheo, D., Abbruzzese, G., and Tabaton, M. (2000) Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 287, 65–67
27. Petrucelli, L., O'Farrell, C., Lockhart, P. J., Baptista, M., Kehoe, K., Vink, L., Choi, P., Wolozin, B., Farrer, M., Hardy, J., et al. (2002) Parkin protects against the toxicity associated with mutant α-synuclein. Proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36, 1007–1019
28. Nishimura, N., Bannykh, S., Slabough, S., Matteson, J., Altschuler, Y., Hahn, K., and Balch, W. E. (1999) A di-acidic (DXE) code directs concentration of cargo during export from the endoplasmic reticulum. J. Biol. Chem. 274, 15937–15946
29. Barlowe, C. (2002) COPII-dependent transport from the endoplasmic reticulum. Curr. Opin. Cell Biol. 4, 417–422
30. Narayanan, V., and Scarlata, S. (2001) Membrane binding and self-association of α-synucleins. Biochemistry 40, 9927–9934
31. Volles, M. J., and Lansbury, P. T., Jr. (2002) Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595–4602
32. Nishimura, N., Plutner, H., Hahn, K., and Balch, W. E. (2002) The delta subunit of AP-3 is required for efficient transport of VSV-G from the trans-Golgi network to the cell surface. Proc. Natl. Acad. Sci. USA 99, 6755–6760
33. Mor-Vaknin, N., Punturieri, A., Sitwala, K., and Markovitz, D. M. (2003) Vimentin is secreted by activated macrophages. Nat. Cell Biol. 1, 59–63
34. Nickel, W. (2003) The mystery of nonclassical protein secretion. Eur. J. Biochem. 270, 2109–2119
35. Li, Q. X., Campbell, B. C., McLean, C. A., Thyagarajan, D., Gai, W. P., Kapsa, R. M., Beyreuther, K., Masters, C. L., and Culvenor, J. G. (2002) Platelet α-and γ-synucleins in Parkinson's disease and normal control subjects. J. Alzheimers Dis. 4, 309–315
36. Hashimoto, M., Yoshimoto, M., Sisk, A., Hsu, L. J., Sundsmo, M., Kittel, A., Saitoh, T., Miller, A., and Masliah, E. (1997) NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. Biochem. Biophys. Res. Commun. 237, 611–616
37. DeMattos, R. B., Bales, K. R., Parsadanian, M., O'Dell, M. A., Foss, E. M., Paul, S. M., and Holtzman, D. M. (2002) Plaque-associated disruption of CSF and plasma amyloid-beta (Aβ) equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 81, 229–236
38. DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., and Holtzman, D. M. (2002) Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264–2267
39. Solano, S. M., Miller, D. W., Augood, S. J., Young, A. B., and Penney, J. B., Jr. (2000) Expression of α-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. Ann. Neurol. 47, 201–210
40. Giasson, B. I., Duda, J. E., Murray, I. V., Chen, Q., Souza, J. M., Hurtig, H. I., Ischiropoulos, H., Trojanowski, J. Q., and Lee, V. M. (2000) Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290, 985–989
41. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., and Iwatsubo, T. (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2, 160–164
42. Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., and Selkoe, D. J. (2001) Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263–269
43. Goldberg, M. S., and Lansbury, P. T., Jr. (2000) Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2, 115–119
44. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., and Mucke, L. (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265–1269